Related Experiment Video
Updated: Aug 4, 2026
07:47
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Published on: October 29, 2019
Management of intrathecal catheter-tip inflammatory masses: a consensus statement
Samuel Hassenbusch1, Kim Burchiel, Robert J Coffey
1Department of Neurological Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. samuel@neosoft.com
Pain Medicine (Malden, Mass.)
|April 22, 2004
Summary
Timely diagnosis and minimally invasive treatment of drug administration catheter-tip inflammatory masses are crucial. Stopping drug delivery can lead to mass shrinkage, and lower intrathecal opioid doses may reduce incidence.
Area of Science:
- Neurology
- Pain Management
- Medical Devices
Background:
- Drug administration catheter-tip inflammatory masses pose a risk, particularly in patients with chronic pain receiving intrathecal therapies.
- Understanding the etiology and clinical presentation is key to effective management.
Purpose of the Study:
- To provide recommendations for the detection, treatment, mitigation, and prevention of catheter-tip inflammatory masses.
- To formulate hypotheses regarding the causes of these masses.
Main Methods:
- Review of published and unpublished case reports.
- Analysis of authors' clinical experiences.
- Formulation of theoretical mitigation and prevention strategies.
Main Results:
- Masses primarily occur in chronic pain patients on intrathecal opioid drugs or unapproved intrathecal agents.
- Diagnostic clues include loss of analgesic effect and progressive neurological symptoms.
- Early diagnosis allows for non-surgical treatment; cessation of drug delivery can cause mass regression (2-5 months).
Conclusions:
- Vigilant follow-up and a high index of suspicion facilitate early diagnosis and minimally invasive treatment, preventing neurological injury.
- Optimizing catheter placement (lumbar thecal sac) and minimizing intrathecal opioid dosage may reduce mass severity and incidence.
